Evidence map›Paper›PMID 38557119›Full record

ArticleCirculation research2024

CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation.

Junxiong Chen, Yingjun Ding, Chao Jiang, Rongmei Qu, Jonathan D Wren, Constantin Georgescu, Xuejun Wang, Darlene N Reuter, Beibei Liu, Cory B Giles and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Cell-Specific Roles of Angiopoietin-2 in CKD.Journal of the American Society of Nephrology : JASN · 2026
    Article
  2. Sex-biased Genetic Risk Loci and Causal Brain Proteins in Parkinson's Disease.medRxiv : the preprint server for health sciences · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 6 countries.

Junxiong ChenUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Yingjun Ding *University of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0003-4123-6848
Chao Jiang *University of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Rongmei QuUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Jonathan D WrenOklahoma Medical Research Foundation, Oklahoma City, OK (J.D.W., C.G., C.B.G.).ORCID 0000-0003-2776-3545
Constantin GeorgescuOklahoma Medical Research Foundation, Oklahoma City, OK (J.D.W., C.G., C.B.G.).
Xuejun WangUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0001-7869-7993
Darlene N ReuterUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0002-0067-9418
Beibei LiuUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Cory B GilesOklahoma Medical Research Foundation, Oklahoma City, OK (J.D.W., C.G., C.B.G.).ORCID 0000-0002-7745-5914
Christoph H MayrHelmholtz Munich, Germany (C.H.M., H.B.S.).ORCID 0000-0001-5353-4768
Herbert B SchillerHelmholtz Munich, Germany (C.H.M., H.B.S.).
Jingxing DaiUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0002-9339-9174
Christopher S StippUniversity of Iowa, Iowa City, IA (C.S.S.).
Bharathiraja SubramaniyanUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Jie WangUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Houjuan ZuoUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Chao HuangUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Kar-Ming FungUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).
Heather C RiceUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0002-5818-4338
Arnoud SonnenbergNetherlands Cancer Institute, Amsterdam, Netherlands (A.S.).ORCID 0000-0001-9585-468X
David WuUniversity of Chicago, IL (D.W.).ORCID 0000-0003-3162-3238
Matthew S WaltersUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0003-0010-8444
You-Yang ZhaoAnn & Robert H. Lurie Children's Hospital of Chicago, IL (Y.-Y.Z.).ORCID 0000-0002-0041-0339
Tomoharu KanieUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0002-2084-1451
Franklin A HaysUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0002-2191-558X
James F PapinUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0001-9894-8243
Dao Wen WangNorthwestern University Feinberg School of Medicine, Chicago, IL (Y.-Y.Z.).ORCID 0000-0002-9774-3980
Xin A ZhangUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK (J.C., Y.D., C.J., R.Q., X.W., D.N.R., B.L., J.D., B.S., J.W., H.Z., C.H., K.-M.F., H.C.R., M.S.W., T.K., F.A.H., J.F.P., X.A.Z.).ORCID 0000-0001-5074-3847
University of Oklahoma Health Sciences Center · USHi-Z Technology (United States) · USOklahoma Medical Research Foundation · USHelmholtz Zentrum München · DENorthwestern University · USDutch Cancer Society · NLGTx (United States) · USJacobson Holman (United States) · USUniversity of Illinois Chicago · USUniversity of Iowa · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
Novel mechanisms of obliterative pulmonary vascular remodeling and sever pulmonary arterial hypertensionR01HL133951 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ZHAO, YOU-YANG · 2016 to 2024
$4.9M
Negative regulators of endothelial regeneration in aging lungs and ARDSR01HL164014 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2022 to 2025
$2.7M
Novel roles of RNA modifications in the pathogenesis of pulmonary vascular remodeling and PAHR01HL162299 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2022 to 2025
$2.6M
Novel mechanisms of endothelial Injury in the pathogenesis of ARDSR01HL148810 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI ZHAO, YOU-YANG · 2020 to 2023
$2.3M
Novel intrinsic endothelial stem cells responsible for lung endothelial regeneration and vascular repair in ARDSR01HL172447 · NHLBI · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI YOU-YANG ZHAO · 2024 to 2026
$2.3M
How Tetraspanins Regulate Vascular MorphogenesisR01HL137819 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2017 to 2020
$1.6M
Tetraspanin-enriched microdomains and endothelial barrier functionR01HL132553 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2017 to 2020
$1.5M
How Tetraspanins Regulate SepsisR01GM135547 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2020 to 2023
$1.4M
How Endothelial Tetraspanins Inhibit InflammationR01HL173312 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2025 to 2025
$730k
NCI NIH HHS P30 CA225520NHLBI NIH HHS R01 HL132553NHLBI NIH HHS R01 HL133951NHLBI NIH HHS R01 HL137819NHLBI NIH HHS R01 HL148810NHLBI NIH HHS R01 HL162299NHLBI NIH HHS R01 HL164014NHLBI NIH HHS R01 HL172447NHLBI NIH HHS R01 HL173312NIGMS NIH HHS P20 GM103639NIGMS NIH HHS R01 GM135547
6 · The paper itself

Abstract

backgroundTetraspanin CD151 is highly expressed in endothelia and reinforces cell adhesion, but its role in vascular inflammation remains largely unknown.

methodsIn vitro molecular and cellular biological analyses on genetically modified endothelial cells, in vivo vascular biological analyses on genetically engineered mouse models, and in silico systems biology and bioinformatics analyses on CD151-related events.

resultsEndothelial ablation of

conclusionsDistinct from its canonical function in strengthening cell adhesion at cell surface, CD151 maintains endolysosome function by sustaining VCP/p97-mediated protein unfolding and turnover. By supporting protein quality control and protein degradation, CD151 prevents proteins from (1) buildup in endolysosomes and (2) discharge through exosomes, to limit vascular inflammation. Also, our study conceptualizes that balance between degradation and discharge of proteins in endothelial cells determines vascular information. Thus, the IFITM3/V-ATPase-tetraspanin-VCP/p97 complexes on endolysosome, as a protein quality control and inflammation-inhibitory machinery, could be beneficial for therapeutic intervention against vascular inflammation.

Indexed as

COVID-19EndosomesLysosomesTetraspanin 24AnimalsHumansInflammationMiceMice, Inbred C57BLMice, KnockoutSARS-CoV-2SepsisVasculitisCD151 protein, humanTetraspanin 24cell adhesionendothelial cellsmultivesicular bodiesproteolysisubiquitin

Identifiers

PMID38557119
PMCPMC11081830
OpenAlexW4393382027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.